Nalidixic acid—a good marker of fluoroquinolone resistance mechanisms in Escherichia coli
Microbiology Spectrum · 2025
DOI: 10.1128/spectrum.01974-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Sofia Kalinen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedicine, University of Turku, Turku, Finland. Hauptthemen laut MEDLINE: Nalidixic Acid, Escherichia coli, Anti-Bacterial Agents, Fluoroquinolones. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sigrid Juséliuksen Säätiö (Sigrid Jusélius Stiftelse), Cancer foundation Finland, Turku University hospital foundation.
Abstract (Originalsprache)
The purpose of this study was to evaluate how ciprofloxacin, pefloxacin, and nalidixic acid disks perform in screening fluoroquinolone resistance mechanisms in 278 Escherichia coli isolates collected from a prospective clinical material. Antimicrobial susceptibility testing of ciprofloxacin, pefloxacin, and nalidixic acid was performed with the disk diffusion method. PCR-based and sequencing methods were used to detect chromosomal mutations in the gyrA and parC genes and the presence of plasmid-mediated qnr and aac(6′)-1b-cr genes. In addition, whole-genome sequencing was used to confirm these results. Our results show that fluoroquinolone resistance mechanisms were discovered, even in ciprofloxacin-susceptible isolates, and plasmid-mediated low-level fluoroquinolone resistance is easily missed if only ciprofloxacin disk is used. E. coli strains with chromosomal gyrA and/or parC mutations were well detected with pefloxacin disk. However, nalidixic acid was a superior tool to detect and differentiate between low- (plasmid-mediated) and high-level (chromosomal mutations) fluoroquinolone resistance in E. coli . Thus, more clinical studies are needed to evaluate the clinical relevance of fluoroquinolone resistance mechanisms in enteric bacteria and pathogens that show potential but are not yet phenotypically fluoroquinolone-resistant. IMPORTANCE We show in our clinical setting that fluoroquinolone resistance mechanisms are discovered, even among phenotypically fluoroquinolone-susceptible Escherichia coli isolates. When plasmid-mediated quinolone-resistance determinants are present, they are a potential risk for treatment failures due to accumulation of resistance mechanisms during the antimicrobial treatment. Therefore, when it is clinically relevant, fluoroquinolone resistance mechanisms in E. coli should be monitored more closely, and we also recommend testing nalidixic acid susceptibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedicine, University of Turku, Turku, Finland.
- Department of Clinical Microbiology, Turku Clinical Microbiome Bank, Turku University Hospital, Turku, Finland.
- Department of Urology, Turku University Hospital, Turku, Finland.
ORCID-Profile: Marianne Gunell
Förderung
- Sigrid Juséliuksen Säätiö (Sigrid Jusélius Stiftelse)
- Cancer foundation Finland
- Turku University hospital foundation
- Finnish Governmental Special Funding
- Turku Combined Research Funding
Zitieren
APA
Kalinen, S., Kallio, H., Kallonen, T., Knaapila, J., Lamminen, T., Huovinen, P., Boström, P., Hakanen, A. J., & Gunell, M. (2025). Nalidixic acid—a good marker of fluoroquinolone resistance mechanisms in Escherichia coli. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01974-24
Vancouver
Kalinen S, Kallio H, Kallonen T, Knaapila J, Lamminen T, Huovinen P, et al. Nalidixic acid—a good marker of fluoroquinolone resistance mechanisms in Escherichia coli. Microbiology Spectrum. 2025. doi:10.1128/spectrum.01974-24
BibTeX
@article{Kalinen2025,
author = {Kalinen, Sofia and Kallio, Heini and Kallonen, Teemu and Knaapila, Juha and Lamminen, Tarja and Huovinen, Pentti and Boström, Peter and Hakanen, Antti J and Gunell, Marianne},
title = {Nalidixic acid—a good marker of fluoroquinolone resistance mechanisms in Escherichia coli},
journal = {Microbiology Spectrum},
year = {2025},
doi = {10.1128/spectrum.01974-24}
}
EUVIMED